Intraperitoneal injection of these exosomes activates the AKT/GSK-3β pathway in the brain to inhibit tau phosphorylation, effectively preventing neuronal death and alleviating AD symptoms both in vitro and in vivo [127]. Here, MAPT is linked to Alzheimer disease.